Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) EBITDA: 2009-2024

Historic EBITDA for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to -$6.4 million.

  • Cumberland Pharmaceuticals' EBITDA fell 15.98% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.3 million, marking a year-over-year increase of 69.70%. This contributed to the annual value of -$6.4 million for FY2024, which is 32.68% up from last year.
  • Cumberland Pharmaceuticals' EBITDA amounted to -$6.4 million in FY2024, which was up 32.68% from -$9.6 million recorded in FY2023.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBITDA peaked at -$5.7 million during FY2022, and registered a low of -$9.6 million during FY2023.
  • Its 3-year average for EBITDA is -$7.2 million, with a median of -$6.4 million in 2024.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' EBITDA crashed by 79.94% in 2020 and then soared by 32.68% in 2024.
  • Cumberland Pharmaceuticals' EBITDA (MRY) stood at -$6.4 million in 2020, then fell by 20.31% to -$7.7 million in 2021, then grew by 25.69% to -$5.7 million in 2022, then plummeted by 67.48% to -$9.6 million in 2023, then skyrocketed by 32.68% to -$6.4 million in 2024.
  • Its EBITDA was -$6.4 million in FY2024, compared to -$9.6 million in FY2023 and -$5.7 million in FY2022.